iOrganBio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

iOrganBio is an early-stage, private biotech focused on creating implantable, bioengineered organ replacements to solve the organ transplant crisis. The company leverages a proprietary platform integrating patient-derived stem cells, 3D bioprinting of biocompatible scaffolds, and advanced tissue maturation processes. While still in pre-clinical development, its technology holds transformative potential for treating end-stage organ failure. The company is likely pre-revenue and backed by venture capital, operating in a high-risk, high-reward segment of the regenerative medicine field.

Organ FailureTransplantation

Technology Platform

Integrated platform combining patient-derived iPSCs, proprietary 3D bioprinting of vascularized scaffolds, and advanced bioreactor maturation to create bioengineered organ replacements.

Opportunities

The company addresses the massive and growing unmet need for transplantable organs, with a potential multi-billion dollar market per organ type.

Advances in stem cell biology, gene editing, and bioprinting materials are creating converging tailwinds for the field.

There is also potential for platform application in high-fidelity disease modeling and drug testing.

Risk Factors

The scientific and engineering challenges of creating functional, vascularized human organs at scale are immense and unproven.

The regulatory pathway for a first-in-class bioengineered organ is lengthy, uncertain, and costly.

The company faces long development timelines (10+ years) and significant burn rate, requiring continual access to large amounts of capital.

Competitive Landscape

iOrganBio competes in a nascent but crowded space including other bioprinting firms (e.g., Aspect Biosystems, CELLINK), stem cell therapy companies, and academic consortia. A major competitive threat is the rapid progress in xenotransplantation (genetically modified pig organs), which is closer to clinical reality. Large medtech companies may also enter the space through acquisition or internal R&D.

More companies in Regenerative Medicine →More companies in United States →